BioSpace News Archive

Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) announces it has entered into an Agreement and Plan of Merger (the “Definitive Merger Agreement”) with privately held Catheter Precision, Inc. (“Catheter Precision”), a medical device and technology company focused in the field of cardiac electrophysiology.

Henry Schein, Inc. (Nasdaq: HSIC) today announced its lineup of products and solutions at the American Association of Oral and Maxillofacial Surgeons (AAOMS) Annual Conference in New Orleans, La. from September 12 through September 17.

Verge Genomics announced that Fierce Biotech named it as a 2022 “Fierce 15” recipient, a recognition given to the biopharmaceutical industry’s most promising early-stage companies.

ReCode Therapeutics , a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Mednow Inc. will participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022.

Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that it has entered into a distribution agreement with IPS Genomix s.a.l. (“IPS”), a medical diagnostics distributor with offices in Beirut, Lebanon and Dubai, UAE.

Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced the appointment of Garry Nicholson as chairman of its board of directors.

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced it has entered into a non-dilutive royalty financing agreement with OrbiMed for up to $250 million.

Agenus announced the appointment of Patricia Carlos as Chief Regulatory, Quality, and Safety Officer; Todd Yancey, MD as Global Clinical Development, Medical Affairs and Commercial Development Advisor.

Anixa Biosciences, Inc. today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia, Senior Member of the Immunology Department at Moffitt Cancer Center, will be speaking at the Rivkin Center and American Association for Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium.